Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24139505 | 0.89 | ALDH1A1 (0.44) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL24139593 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HSD11B1LMNAMEN1KMT2A | |
| SCHEMBL24139596 | 0.84 | HSD11B1 (0.42) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL24139813 | 0.84 | ALDH1A1 (0.40) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL29319296 | 0.83 | HSD11B1 (0.41) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL29319280 | 0.83 | HSD11B1 (0.41) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL29319290 | 0.83 | ALDH1A1 (0.40) | ALDH1A1HSD11B1LMNAMEN1KMT2A | |
| SCHEMBL29319286 | 0.82 | ALDH1A1 (0.39) | ALDH1A1HSD11B1LMNAMEN1KMT2A | |
| SCHEMBL29319299 | 0.81 | HSD11B1 (0.40) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B | |
| SCHEMBL29319269 | 0.81 | HSD11B1 (0.46) | ALDH1A1HSD11B1LMNAGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2021262426-A9 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021262426-A2 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | ALDH1A1 2758/4885HSD11B1 2165/4885LMNA 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.